Pfizer (PFE) : Analyst Rating Update

Pfizer (PFE) has an average broker rating of 1.8, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 9 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Pfizer (PFE) : The highest short term price target forecast on Pfizer (PFE) is $54 and the lowest target price is $33. A total of 13 equity analysts are currently covering the company. The average price of all the analysts is $38.92 with a standard deviation of $5.56.

Pfizer (NYSE:PFE): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.82 and $35.38 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.90. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.86, notching a gain of 0.14% for the day. The total traded volume was 25,832,015 . The stock had closed at $35.81 on the previous day.

Also, Brokerage firm Jefferies maintains its rating on Pfizer (NYSE:PFE). As per the latest information, the brokerage house lowers the price target to $40 per share from a prior target of $42. The shares have been rated Buy. The rating by the firm was issued on June 20, 2016. The company shares have rallied 7.06% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $36.46 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $34.55 and the 200 Day Moving Average price is recorded at $32.01.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.